Pradaxa (Dabigatran Etexilate Mesylate) Patent Expiration, LOE Window & CMS Spending
Pradaxa (Dabigatran Etexilate Mesylate) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2026-03-07 (last listed 2031-07-20), 8 AB generics, $131.9M 2024 CMS Part D & Medicaid spend, and $4,717 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N022512 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2026-03-07 |
| Last Listed Patent or Exclusivity Date | 2031-07-20 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $131.9M |
| 2024 Medicare Part D Spend | $123.2M |
| 2024 Medicaid Spend | $8.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($4,717 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.